InvestorsHub Logo
Followers 7
Posts 195
Boards Moderated 0
Alias Born 03/06/2021

Re: Lemmiwinks post# 335492

Thursday, 04/15/2021 5:12:29 PM

Thursday, April 15, 2021 5:12:29 PM

Post# of 426563
Amarin did add this (below)
after a few of us wrote in last year. My guess is they are waiting on
Dr Mason's presentation to highlight the encapsulation patent and oxidation issues of generic Vascepa. Dr Nelson has an interesting presentation tomorrow that might touch on some comparisons.

"VASCEPA follows strict regulatory standards with a patented 3-month manufacturing process qualified to meet FDA drug standards. This process ensures the consistency and stability of VASCEPA. This is important because, if damaged, the safety and efficacy of the active ingredient can vary and is highly vulnerable to derivatives and oxidation/spoilage."

https://www.vascepa.com/about-vascepa/history
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News